{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T08:30:56Z","timestamp":1786437056119,"version":"build-2736575974"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s11523-026-01210-7","type":"journal-article","created":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T17:52:44Z","timestamp":1776793964000},"page":"447-457","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Isatuximab: A Review in Transplant-Ineligible Newly Diagnosed Multiple Myeloma"],"prefix":"10.1007","volume":"21","author":[{"given":"Sheridan M.","family":"Hoy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,21]]},"reference":[{"issue":"3","key":"1210_CR1","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1182\/blood.2022017635","volume":"143","author":"T Facon","year":"2024","unstructured":"Facon T, Leleu X, Manier S. How I treat multiple myeloma in geriatric patients. Blood. 2024;143(3):224\u201332.","journal-title":"Blood"},{"issue":"1","key":"1210_CR2","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1186\/s12885-020-07503-y","volume":"20","author":"R Fonseca","year":"2020","unstructured":"Fonseca R, Usmani SZ, Mehra M, et al. Frontline treatment patterns and attrition rates by subsequent lines of therapy in patients with newly diagnosed multiple myeloma. BMC Cancer. 2020;20(1):1087.","journal-title":"BMC Cancer"},{"issue":"9","key":"1210_CR3","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/s41408-020-00359-2","volume":"10","author":"SV Rajkumar","year":"2020","unstructured":"Rajkumar SV, Kumar S. Multiple myeloma current treatment algorithms. Blood Cancer J. 2020;10(9):94.","journal-title":"Blood Cancer J"},{"issue":"1","key":"1210_CR4","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1182\/hematology.2024000580","volume":"2024","author":"A Perrot","year":"2024","unstructured":"Perrot A. Transplant in myeloma: who, when, and why? Hematol Am Soc Hematol Educ Program. 2024;2024(1):561\u20138.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"4","key":"1210_CR5","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.jgo.2020.12.001","volume":"12","author":"SJ Grant","year":"2021","unstructured":"Grant SJ, Mian HS, Giri S, et al. Transplant-ineligible newly diagnosed multiple myeloma: current and future approaches to clinical care: a Young International Society of Geriatric Oncology review paper. J Geriatr Oncol. 2021;12(4):499\u2013507.","journal-title":"J Geriatr Oncol"},{"issue":"4","key":"1210_CR6","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s40265-019-01080-6","volume":"79","author":"YY Syed","year":"2019","unstructured":"Syed YY. Daratumumab: a review in combination therapy for transplant-ineligible newly diagnosed multiple myeloma. Drugs. 2019;79(4):447\u201354.","journal-title":"Drugs"},{"key":"1210_CR7","unstructured":"Sanofi Winthrop Industrie. SARCLISA 20 mg\/mL concentrate for solution for infusion: EU summary of product characteristics. 2025. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/sarclisa. Accessed 18 Mar 2026."},{"key":"1210_CR8","unstructured":"sanofi-aventis U.S. LLC. SARCLISA\u00ae (isatuximab-irfc) injection, for intravenous use: US prescribing information. 2024. https:\/\/www.fda.gov\/. Accessed 18 Mar 2026."},{"issue":"1","key":"1210_CR9","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1182\/blood-2017-06-740944","volume":"131","author":"N van de Donk","year":"2018","unstructured":"van de Donk N, Richardson PG, Malavasi F. CD38 antibodies in multiple myeloma: back to the future. Blood. 2018;131(1):13\u201329.","journal-title":"Blood"},{"issue":"10","key":"1210_CR10","doi-asserted-by":"publisher","first-page":"3176","DOI":"10.1158\/1078-0432.CCR-18-1597","volume":"25","author":"L Moreno","year":"2019","unstructured":"Moreno L, Perez C, Zabaleta A, et al. The mechanism of action of the anti-CD38 monoclonal antibody isatuximab in multiple myeloma. Clin Cancer Res. 2019;25(10):3176\u201387.","journal-title":"Clin Cancer Res"},{"issue":"9","key":"1210_CR11","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1038\/s41571-025-01041-x","volume":"22","author":"MA Dimopoulos","year":"2025","unstructured":"Dimopoulos MA, Terpos E, Boccadoro M, et al. EHA-EMN evidence-based guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma. Nat Rev Clin Oncol. 2025;22(9):680\u2013700.","journal-title":"Nat Rev Clin Oncol"},{"key":"1210_CR12","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in oncology: multiple myeloma. Version 5.2026\u2014January 9, 2026. 2026. https:\/\/www.nccn.org\/. Accessed 18 Mar 2026."},{"issue":"9","key":"1210_CR13","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1007\/s40265-020-01311-1","volume":"80","author":"S Dhillon","year":"2020","unstructured":"Dhillon S. Isatuximab: first approval. Drugs. 2020;80(9):905\u201312.","journal-title":"Drugs"},{"issue":"5","key":"1210_CR14","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1007\/s11523-021-00827-0","volume":"16","author":"JE Frampton","year":"2021","unstructured":"Frampton JE. Isatuximab: a review of its use in multiple myeloma. Target Oncol. 2021;16(5):675\u201386.","journal-title":"Target Oncol"},{"issue":"11","key":"1210_CR15","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1200\/JCO-24-02266","volume":"43","author":"EK Mai","year":"2025","unstructured":"Mai EK, Bertsch U, Pozek E, et al. Isatuximab, lenalidomide, bortezomib, and dexamethasone induction therapy for transplant-eligible newly diagnosed multiple myeloma: final part 1 analysis of the GMMG-HD7 trial. J Clin Oncol. 2025;43(11):1279\u201388.","journal-title":"J Clin Oncol"},{"key":"1210_CR16","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.3389\/fimmu.2020.01771","volume":"11","author":"C Zhu","year":"2020","unstructured":"Zhu C, Song Z, Wang A, et al. Isatuximab acts through Fc-dependent, independent, and direct pathways to kill multiple myeloma cells. Front Immunol. 2020;11:1771.","journal-title":"Front Immunol"},{"issue":"15","key":"1210_CR17","doi-asserted-by":"publisher","first-page":"4290","DOI":"10.1158\/1078-0432.CCR-16-3192","volume":"23","author":"X Feng","year":"2017","unstructured":"Feng X, Zhang L, Acharya C, et al. Targeting CD38 suppresses induction and function of T regulatory cells to mitigate immunosuppression in multiple myeloma. Clin Cancer Res. 2017;23(15):4290\u2013300.","journal-title":"Clin Cancer Res"},{"issue":"20","key":"1210_CR18","doi-asserted-by":"publisher","first-page":"20332","DOI":"10.1002\/cam4.6619","volume":"12","author":"K Bisht","year":"2023","unstructured":"Bisht K, Fukao T, Chiron M, et al. Immunomodulatory properties of CD38 antibodies and their effect on anticancer efficacy in multiple myeloma. Cancer Med. 2023;12(20):20332\u201352.","journal-title":"Cancer Med"},{"issue":"10","key":"1210_CR19","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1007\/s00277-022-04917-5","volume":"101","author":"X Leleu","year":"2022","unstructured":"Leleu X, Martin T, Weisel K, et al. Anti-CD38 antibody therapy for patients with relapsed\/refractory multiple myeloma: differential mechanisms of action and recent clinical trial outcomes. Ann Hematol. 2022;101(10):2123\u201337.","journal-title":"Ann Hematol"},{"issue":"4","key":"1210_CR20","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1093\/jalm\/jfae028","volume":"9","author":"K Thoren","year":"2024","unstructured":"Thoren K, Menad S, Nouadje G, et al. Isatuximab-specific immunofixation electrophoresis assay to remove interference in serum M-protein measurement in patients with multiple myeloma. J Appl Lab Med. 2024;9(4):661\u201371.","journal-title":"J Appl Lab Med."},{"issue":"11","key":"1210_CR21","doi-asserted-by":"publisher","first-page":"2334","DOI":"10.1111\/trf.17137","volume":"62","author":"B Chami","year":"2022","unstructured":"Chami B, Okuda M, Moayeri M, et al. Anti-CD38 monoclonal antibody interference with blood compatibility testing: differentiating isatuximab and daratumumab via functional epitope mapping. Transfusion (Paris). 2022;62(11):2334\u201348.","journal-title":"Transfusion (Paris)."},{"issue":"7","key":"1210_CR22","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1038\/s41375-023-01936-7","volume":"37","author":"EM Ocio","year":"2023","unstructured":"Ocio EM, Perrot A, Bories P, et al. Efficacy and safety of isatuximab plus bortezomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma ineligible\/with no immediate intent for autologous stem cell transplantation. Leukemia. 2023;37(7):1521\u20139.","journal-title":"Leukemia"},{"issue":"2","key":"1210_CR23","doi-asserted-by":"publisher","first-page":"e120","DOI":"10.1016\/S2352-3026(24)00347-8","volume":"12","author":"FB Askeland","year":"2025","unstructured":"Askeland FB, Hauk\u00e5s E, Sl\u00f8rdahl TS, et al. Isatuximab, bortezomib, lenalidomide, and limited dexamethasone in patients with transplant-ineligible multiple myeloma (REST): a multicentre, single-arm, phase 2 trial. Lancet Haematol. 2025;12(2):e120\u20137.","journal-title":"Lancet Haematol."},{"issue":"8","key":"1210_CR24","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1038\/s41591-024-03050-2","volume":"30","author":"X Leleu","year":"2024","unstructured":"Leleu X, Hulin C, Lambert J, et al. Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial. Nat Med. 2024;30(8):2235\u201341.","journal-title":"Nat Med"},{"key":"1210_CR25","doi-asserted-by":"crossref","unstructured":"Corre J, Lambert J, Bobin A, et al. ISA-VRD improves outcomes in high-risk (HR) newly diagnosed transplant-ineligible multiple myeloma (NDMM TI) using the IMS\/IMWG consensus HR definition: results from the BENEFIT phase 3 trial [abstract no. PF727]. HemaSphere. 2025;9(S1).","DOI":"10.1016\/S2152-2650(25)03843-1"},{"issue":"17","key":"1210_CR26","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1056\/NEJMoa2400712","volume":"391","author":"T Facon","year":"2024","unstructured":"Facon T, Dimopoulos MA, Leleu XP, et al. Isatuximab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2024;391(17):1597\u2013609.","journal-title":"N Engl J Med"},{"key":"1210_CR27","unstructured":"European Medicines Agency. SARCLISA (isatuximab): EU assessment report (reference number EMA\/555367\/2024). 2024. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/sarclisa. Accessed 18 Mar 2026."},{"issue":"9","key":"1210_CR28","first-page":"2139","volume":"110","author":"S Manier","year":"2025","unstructured":"Manier S, Dimopoulos MA, Leleu XP, et al. Isatuximab plus bortezomib, lenalidomide, and dexamethasone for transplant-ineligible newly diagnosed multiple myeloma patients: a frailty subgroup analysis of the IMROZ trial. Haematologica. 2025;110(9):2139\u201350.","journal-title":"Haematologica"},{"issue":"Suppl 1","key":"1210_CR29","doi-asserted-by":"publisher","first-page":"7055","DOI":"10.1182\/blood-2024-199908","volume":"144","author":"G An","year":"2024","unstructured":"An G, Liu Z, Jin J, et al. Isatuximab plus bortezomib, lenalidomide, and dexamethasone (Isa-VRd) versus Vrd in Chinese patients with newly diagnosed multiple myeloma who are ineligible for transplant: IMROZ subgroup analysis [abstract]. Blood. 2024;144(Suppl 1):7055.","journal-title":"Blood"},{"key":"1210_CR30","doi-asserted-by":"crossref","unstructured":"Dimopoulos MA, Leleu XP, Beksac M, et al. Isatuximab, bortezomib, lenalidomide, and dexamethasone (Isa-VRd) in newly diagnosed multiple myeloma (NDMM): outcomes in patients with 1q21+ status in the phase 3 IMROZ study [abstract no. 7517]. J Clin Oncol. 2025;43(16 Suppl).","DOI":"10.1200\/JCO.2025.43.16_suppl.7517"},{"key":"1210_CR31","unstructured":"Zamagni E, Facon T, Dimopoulos MA, et al. Isatuximab, bortezomib, lenalidomide, dexamethasone (ISA-VRD) in patients with transplant-ineligible (TI) newly diagnosed multiple myeloma (NDMM) and plasmacytomas: IMROZ subgroup analysis [abstract no. PF750]. HemaSphere. 2025;9(S1)."},{"key":"1210_CR32","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2025030120","author":"RZ Orlowski","year":"2026","unstructured":"Orlowski RZ, Dimopoulos MA, Leleu X, et al. Isatuximab, bortezomib, lenalidomide, dexamethasone for multiple myeloma: dynamics of MRD-negativity in the IMROZ study. Blood. 2026. https:\/\/doi.org\/10.1182\/blood.2025030120.","journal-title":"Blood"},{"issue":"Suppl 1","key":"1210_CR33","doi-asserted-by":"publisher","first-page":"3352","DOI":"10.1182\/blood-2024-207087","volume":"144","author":"M Dimopoulos","year":"2024","unstructured":"Dimopoulos M, Facon T, Beksac M, et al. Health-related quality of life (HRQoL) in patients with newly diagnosed multiple myeloma (NDMM) ineligible for transplantation and treated with isatuximab, bortezomib, lenalidomide, and dexamethasone (Isa-VRd) vs Vrd alone: results from the IMROZ study [abstract]. Blood. 2024;144(Suppl 1):3352\u20135.","journal-title":"Blood"},{"issue":"11","key":"1210_CR34","doi-asserted-by":"publisher","first-page":"e810","DOI":"10.1016\/S2352-3026(22)00263-0","volume":"9","author":"H Goldschmidt","year":"2022","unstructured":"Goldschmidt H, Mai EK, Bertsch U, et al. Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial. Lancet Haematol. 2022;9(11):e810\u201321.","journal-title":"Lancet Haematol"},{"issue":"Suppl 1","key":"1210_CR35","doi-asserted-by":"publisher","first-page":"8956","DOI":"10.4081\/hr.2020.8956","volume":"12","author":"D Derudas","year":"2020","unstructured":"Derudas D, Capraro F, Martinelli G, et al. How I manage frontline transplant-ineligible multiple myeloma. Hematol Rep. 2020;12(Suppl 1):8956.","journal-title":"Hematol Rep"},{"issue":"14","key":"1210_CR36","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1200\/JCO.18.02096","volume":"37","author":"J Mikhael","year":"2019","unstructured":"Mikhael J, Ismaila N, Cheung MC, et al. Treatment of multiple myeloma: ASCO and CCO joint clinical practice guideline. J Clin Oncol. 2019;37(14):1228\u201363.","journal-title":"J Clin Oncol"},{"key":"1210_CR37","doi-asserted-by":"publisher","DOI":"10.37349\/etat.2025.1002300","volume":"6","author":"DT Jones","year":"2025","unstructured":"Jones DT, Aboaid H, Srinivasmurthy R, et al. A systematic review and meta-analysis of phase III randomized controlled trials to assess the risk of pneumonia, URTIs, and VTE in multiple myeloma patients treated with isatuximab. Explor Targeted Antitumor Ther. 2025;6:1002300.","journal-title":"Explor Targeted Antitumor Ther"},{"key":"1210_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2025.101287","volume":"72","author":"A Kannan","year":"2025","unstructured":"Kannan A, Jeffrey K, Misbah S, et al. Practical guidance on the prevention and management of infection in multiple myeloma patients: a case-based approach. Blood Rev. 2025;72:101287.","journal-title":"Blood Rev"},{"key":"1210_CR39","doi-asserted-by":"crossref","unstructured":"Bobin A, Morisse M, Zhang R, et al. Multicenter phase 2 study of subcutaneous isatuximab plus bortezomib, lenalidomide, and dexamethasone (ISA SC-VRD) in newly diagnosed transplant-ineligible multiple myeloma (NDMM TI): results from ISASOCUT [abstract no. PS1746]. HemaSphere. 2025;9(S1).","DOI":"10.1182\/blood-2025-2275"}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-026-01210-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11523-026-01210-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-026-01210-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T08:12:34Z","timestamp":1786435954000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11523-026-01210-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,21]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["1210"],"URL":"https:\/\/doi.org\/10.1007\/s11523-026-01210-7","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,21]]},"assertion":[{"value":"8 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This article was originally published under the subscription model but it is now published under an Open Access license.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Sheridan M. Hoy is a salaried employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.","order":1,"name":"Ethics","label":"Authorship and Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethics Approval, Consent to Participate, Consent to Publish, Availability of Data and Material, Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}}]}}